| Website | endocyte.com |
| Category | BioTech |
| Phone | 765-463-7175 |
| info@endocyte.com | |
| Employees | |
| Founded | 1996 |
| TOTAL | $41M |
| FUNDING TOTAL | $41M |
| Series C, 1/10 Sanderling Ventures Burrill & Company American Bailey Ventures Blue Chip Venture Company Triathlon Medical Venture Partners | $26M |
| Venture Round, 8/10 MidCap Financial Silicon Valley Bank | $15M |
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
